Tags

Type your tag names separated by a space and hit enter

Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Int J Mol Sci 2017; 18(4)IJ

Abstract

Drug induced liver injury (DILI) is a potentially serious adverse reaction in a few susceptible individuals under therapy by various drugs. Health care professionals facing DILI are confronted with a wealth of drug-unrelated liver diseases with high incidence and prevalence rates, which can confound the DILI diagnosis. Searching for alternative causes is a key element of RUCAM (Roussel Uclaf Causality Assessment Method) to assess rigorously causality in suspected DILI cases. Diagnostic biomarkers as blood tests would be a great help to clinicians, regulators, and pharmaceutical industry would be more comfortable if, in addition to RUCAM, causality of DILI can be confirmed. High specificity and sensitivity are required for any diagnostic biomarker. Although some risk factors are available to evaluate liver safety of drugs in patients, no valid diagnostic or prognostic biomarker exists currently for idiosyncratic DILI when a liver injury occurred. Identifying a biomarker in idiosyncratic DILI requires detailed knowledge of cellular and biochemical disturbances leading to apoptosis or cell necrosis and causing leakage of specific products in blood. As idiosyncratic DILI is typically a human disease and hardly reproducible in animals, pathogenetic events and resulting possible biomarkers remain largely undisclosed. Potential new diagnostic biomarkers should be evaluated in patients with DILI and RUCAM-based established causality. In conclusion, causality assessment in cases of suspected idiosyncratic DILI is still best achieved using RUCAM since specific biomarkers as diagnostic blood tests that could enhance RUCAM results are not yet available.

Authors+Show Affiliations

Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Germany. rolf.teschke@gmx.de. Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, D-60590 Frankfurt, Germany. rolf.teschke@gmx.de.Institute of Occupational, Environmental and Social Medicine, Medical Faculty, Goethe University Frankfurt, D-60590 Frankfurt, Germany. j.schulze@em.uni-frankfurt.de.Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Germany. Axel_Eickhoff@klinikum-hanau.de. Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, D-60590 Frankfurt, Germany. Axel_Eickhoff@klinikum-hanau.de.Pharmacovigilance Consultancy, F-75020 Paris, France. gaby.danan@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28398242

Citation

Teschke, Rolf, et al. "Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?" International Journal of Molecular Sciences, vol. 18, no. 4, 2017.
Teschke R, Schulze J, Eickhoff A, et al. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int J Mol Sci. 2017;18(4).
Teschke, R., Schulze, J., Eickhoff, A., & Danan, G. (2017). Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? International Journal of Molecular Sciences, 18(4), doi:10.3390/ijms18040803.
Teschke R, et al. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment. Int J Mol Sci. 2017 Apr 11;18(4) PubMed PMID: 28398242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? AU - Teschke,Rolf, AU - Schulze,Johannes, AU - Eickhoff,Axel, AU - Danan,Gaby, Y1 - 2017/04/11/ PY - 2017/02/24/received PY - 2017/03/31/revised PY - 2017/04/01/accepted PY - 2017/4/12/entrez PY - 2017/4/12/pubmed PY - 2017/6/2/medline KW - DILI KW - RUCAM KW - Roussel Uclaf Causality Assessment Method KW - diagnostic biomarkers KW - drug induced liver injury KW - pathogenesis JF - International journal of molecular sciences JO - Int J Mol Sci VL - 18 IS - 4 N2 - Drug induced liver injury (DILI) is a potentially serious adverse reaction in a few susceptible individuals under therapy by various drugs. Health care professionals facing DILI are confronted with a wealth of drug-unrelated liver diseases with high incidence and prevalence rates, which can confound the DILI diagnosis. Searching for alternative causes is a key element of RUCAM (Roussel Uclaf Causality Assessment Method) to assess rigorously causality in suspected DILI cases. Diagnostic biomarkers as blood tests would be a great help to clinicians, regulators, and pharmaceutical industry would be more comfortable if, in addition to RUCAM, causality of DILI can be confirmed. High specificity and sensitivity are required for any diagnostic biomarker. Although some risk factors are available to evaluate liver safety of drugs in patients, no valid diagnostic or prognostic biomarker exists currently for idiosyncratic DILI when a liver injury occurred. Identifying a biomarker in idiosyncratic DILI requires detailed knowledge of cellular and biochemical disturbances leading to apoptosis or cell necrosis and causing leakage of specific products in blood. As idiosyncratic DILI is typically a human disease and hardly reproducible in animals, pathogenetic events and resulting possible biomarkers remain largely undisclosed. Potential new diagnostic biomarkers should be evaluated in patients with DILI and RUCAM-based established causality. In conclusion, causality assessment in cases of suspected idiosyncratic DILI is still best achieved using RUCAM since specific biomarkers as diagnostic blood tests that could enhance RUCAM results are not yet available. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/28398242/Drug_Induced_Liver_Injury:_Can_Biomarkers_Assist_RUCAM_in_Causality_Assessment L2 - http://www.mdpi.com/resolver?pii=ijms18040803 DB - PRIME DP - Unbound Medicine ER -